Greater Trochanteric Bursa Injection

Evidence at a Glance

Greater trochanteric bursa injection treats lateral hip pain of greater trochanteric pain syndrome (GTPS). It is coded as a major joint or bursa injection (20610 without ultrasound, 20611 with ultrasound), not as a trigger point injection. Three coding facts distinguish this procedure from the muscle injections earlier in this series: ultrasound guidance is bundled into 20611 (it is not reported separately), modifier 50 for bilateral injection does apply, and laterality-specific diagnosis coding is required. Prior authorization is generally not required.

Domain	Summary
Medicare NCD	No national coverage determination specific to trochanteric bursa injection. Major joint/bursa injections are broadly covered when medically necessary.
Medicare LCD / Article	Some MAC policies for joint/bursa corticosteroid injection require documented failure of conservative care and set injection frequency expectations. Verify the local policy.
Commercial Coverage	Covered as medically necessary for GTPS refractory to conservative care (Cigna, Aetna, UnitedHealthcare, BCBS plans). Ultrasound guidance may be scrutinized where a landmark injection is feasible.
Evidence Level	Moderate for short-term relief. Modern understanding reframes many cases as gluteal tendinopathy rather than isolated bursitis, which tempers long-term corticosteroid expectations.
Image Guidance	Optional. The bursa is often palpable, so landmark injection (20610) is common. Ultrasound guidance is reported with 20611 (bundled); fluoroscopy is reported as 20610 plus 77002.
Prior Authorization	Usually not required. Not typically managed by interventional-pain UM vendors. Verify plan-specific corticosteroid-injection rules.
Conservative Therapy	Activity modification, physical therapy (gluteal strengthening, hip abductor loading), NSAIDs, and weight management should be documented before injection.
Diagnostic Block	Not applicable. The injection is therapeutic; a local-anesthetic component can confirm the pain source diagnostically within the same encounter.
Key Documentation	Lateral hip pain with point tenderness at the greater trochanter, provocative findings (resisted abduction, side-lying pain), laterality, guidance modality, injectate and units, and pre-/post pain scores.
Approval Considerations	Correct code (20610 vs 20611 by guidance), laterality-specific diagnosis, documented conservative care, and adherence to injection frequency limits.

Procedure Overview

The greater trochanteric bursa lies between the greater trochanter of the femur and the overlying iliotibial band and gluteal musculature. Inflammation or, more commonly, degenerative gluteal tendinopathy at this site produces the lateral hip pain characteristic of greater trochanteric pain syndrome. A trochanteric bursa injection delivers corticosteroid and local anesthetic into the peritrochanteric space to reduce inflammation and pain, typically as part of a program that emphasizes abductor strengthening and load management.

Operationally the procedure is straightforward but carries a specific coding hazard. Because the site is a major bursa, it is billed with the arthrocentesis family (20610/20611), not with trigger point codes - a frequent error when clinicians think of the injection as targeting muscle. The guidance decision (landmark, ultrasound, or fluoroscopy) drives code selection, and getting that mapping right is the difference between clean payment and a guidance-related denial.

Relevant Anatomy (High-Level)

The relevant structures are the greater trochanter, the trochanteric (and subgluteus) bursae, and the gluteus medius and minimus tendons that insert on the trochanter beneath the iliotibial band. Contemporary understanding of GTPS recognizes that pain frequently arises from gluteal tendinopathy and associated bursal reaction rather than isolated bursitis. This distinction matters for expectation-setting and documentation: a corticosteroid injection reliably addresses the inflammatory component but does not correct underlying tendon pathology, which is why durable relief depends on concurrent rehabilitation.

Clinical Indications

Greater trochanteric pain syndrome / trochanteric bursitis with lateral hip pain and point tenderness over the greater trochanter.
Pain reproduced by resisted hip abduction, single-leg stance, or side-lying on the affected hip.
Symptoms persisting despite a documented course of conservative therapy.
Supportive imaging (ultrasound or MRI) showing bursal fluid, bursal wall thickening, or gluteal tendinopathy, where obtained.
Exclusion of hip joint osteoarthritis and lumbar sources as the primary pain generator, or coexisting conditions clearly delineated.

Patient Selection

The ideal candidate has a focal, examination-confirmed lateral hip pain source rather than diffuse hip or referred lumbar pain. Selection should confirm:

Point tenderness localized to the greater trochanter with reproducible provocative findings.
A documented trial of, or contraindication to, conservative management including abductor strengthening.
Functional impairment (gait, stairs, sleep on the affected side) the injection is intended to improve.
Delineation of coexisting hip osteoarthritis or lumbar pathology so the correct pain generator is treated.
Realistic expectations that corticosteroid provides symptomatic relief while rehabilitation addresses the underlying tendinopathy.

Contraindications

Absolute	Relative
Overlying skin or soft-tissue infection.	Therapeutic anticoagulation or bleeding diathesis (individualized).
Known allergy to the planned injectate.	Poorly controlled diabetes (transient glycemic effect of corticosteroid).
Patient refusal or inability to cooperate.	Repeated recent corticosteroid injection at the same site (cumulative risk).

Suspected gluteal tendon tear (corticosteroid may be inadvisable).

Medical Necessity

Medical necessity is established by documenting a localized trochanteric source of pain and the failure of conservative care. Payers commonly expect the record to show:

Lateral hip pain with point tenderness over the greater trochanter.
Provocative findings (resisted abduction, single-leg stance, side-lying pain).
A documented course of conservative therapy and its outcome, including abductor strengthening.
Laterality of the affected hip.
Supportive imaging findings where obtained, and exclusion of competing sources.
The functional deficit treated and the therapeutic goal.

Medicare Coverage Guidance

There is no National Coverage Determination specific to trochanteric bursa injection. Major joint and bursa injections are broadly covered when medically necessary, with details set by each MAC:

Conservative-care condition. Some contractor policies require documented failure of conservative measures before corticosteroid injection of a bursa.
Frequency expectations. Repeated corticosteroid injections at the same site are limited; the record must justify the frequency of injection.
Guidance coding. Ultrasound-guided injection is reported with 20611 (guidance bundled); fluoroscopic guidance is reported as 20610 plus 77002. Billing 20610 when ultrasound guidance was used is a common denial trigger.
Laterality. Laterality-specific diagnosis coding is required, and bilateral injection is reported with modifier 50 or RT/LT per payer instruction.
Documentation. The bursa injected, medication and dose, and the patient's response should be documented, with pre- and post-injection assessment.

Commercial Payer Comparison

Payer / Program	Typical Posture on Trochanteric Bursa Injection
eviCore / Carelon / Cohere / Evolent	Major joint/bursa injections are generally not managed by interventional-pain UM programs; review focuses on spinal and neurostimulation services.
Cigna	Covered for GTPS meeting medical-necessity criteria; conservative-care documentation expected. Ultrasound guidance addressed under separate policy.
Aetna	Considers corticosteroid injection medically necessary for documented trochanteric bursitis/GTPS refractory to conservative care; frequency expectations apply.
UnitedHealthcare	Covers under medical policy for qualifying GTPS; emphasizes documented conservative care and functional impairment.
Humana	Medicare Advantage aligns with CMS/MAC principles; commercial follows medical-necessity criteria with frequency edits.
Blue Cross Blue Shield plans	Plan-specific medical policies; some set annual injection limits per site and require conservative-care documentation. Verify the local licensee policy.

Documentation Requirements

Lateral hip pain with point tenderness at the greater trochanter.
Provocative findings (resisted abduction, side-lying pain).
Laterality (right / left) documented.
Conservative therapy history and outcome.
Pre-injection numeric pain score.
Guidance modality (landmark / ultrasound / fluoroscopy).
For ultrasound: retained permanent image and report (required for 20611).
Bursa injected, medication name, concentration, and dose.
Exclusion / delineation of hip OA and lumbar sources.
Post-injection pain score and immediate percent relief.
Functional impairment and therapeutic goal.
Signed and dated procedure note.

Imaging Requirements

Diagnostic imaging (ultrasound or MRI) is used selectively in the work-up to confirm bursal fluid or gluteal tendinopathy and to exclude tendon tear or hip joint pathology; it is not required in every case where the clinical diagnosis is clear. Procedural guidance is a separate concept. Landmark (palpation-guided) injection is common and appropriate for a palpable bursa. When ultrasound guidance is used, the service is reported with 20611, which includes the guidance and requires a permanent recorded image and report; a separate ultrasound-guidance code is not added. When fluoroscopic guidance is used, report 20610 with 77002. The choice of guidance should be documented along with its rationale.

Prior Authorization Workflow

Benefit verification. Confirm coverage for the injection and any plan conservative-care or frequency conditions; formal authorization is usually not required.
Conservative-care confirmation. Verify that the documented conservative trial satisfies the payer's expectation before scheduling.
Diagnosis validation. Confirm a laterality-specific trochanteric-bursitis diagnosis the record supports.
Guidance decision. Select landmark, ultrasound, or fluoroscopy, and map to the correct code (20610, 20611, or 20610 plus 77002).
Procedure and coding. Report the correct code with laterality (modifier 50 or RT/LT for bilateral), and append modifier 25 only for a separate E/M.
Post-service integrity. Ensure the note carries guidance documentation, laterality, and pre-/post pain scores.

Common Prior Authorization & Claim Denials

Denial Reason	Root Cause / Prevention
Wrong procedure family	Trigger point code billed for a bursa injection. Report 20610/20611 (major joint/bursa), not 20552.
20610 billed when ultrasound was used	Ultrasound-guided injection must be reported with 20611. Map the guidance modality to the correct code.
Guidance not supported	Ultrasound guidance billed without the required permanent image and report, or without documented rationale. Retain the image; document why guidance was needed.
Conservative care not documented	Injection billed without a visible conservative-care trial. Document the trial and outcome before the injection.
Unspecified laterality	Non-laterality diagnosis submitted. Use M70.61 (right) or M70.62 (left); drop to M70.60 only when truly unspecified.
Frequency limit exceeded	Repeated same-site corticosteroid injections beyond the payer limit. Track cumulative injections and justify frequency.
Diagnosis defaults to hip pain	Generic hip-pain code used instead of the specific bursitis code. Code the documented diagnosis (M70.6-), not M25.55-.
Missing pre/post assessment	Record lacks documented pain scores/response. Capture pre-/post scores and percent relief.

Appeal Strategies

Submit the procedure note documenting point tenderness, provocative findings, laterality, injectate and dose, and pre-/post pain scores.
For guidance denials, supply the retained ultrasound image and report (for 20611) or the fluoroscopy documentation (for 77002), plus the rationale for guidance.
For conservative-care denials, attach the documented therapy trial and outcome.
For coding denials, confirm the correct arthrocentesis code and laterality-specific diagnosis were used, and correct where appropriate.
For frequency denials, justify the clinical need and response to prior injections.
Cite the applicable LCD/article or commercial policy establishing criteria were met.

Coding & Billing Overview

Applicable CPT® Codes

CPT®	Descriptor	Application
20610	Arthrocentesis, aspiration and/or injection; major joint or bursa, without ultrasound guidance	Landmark-guided trochanteric bursa injection.
20611	Same, with ultrasound guidance, with permanent recording and reporting	Ultrasound-guided injection; guidance is included (do not add 76942).
77002	Fluoroscopic guidance for needle placement (add-on)	Report with 20610 when fluoroscopy (not ultrasound) is used.

HCPCS (Injectate)

The corticosteroid is reported with the appropriate J-code (for example J1030 methylprednisolone acetate 40 mg, J1040 methylprednisolone acetate 80 mg, or J3301 triamcinolone acetonide per 10 mg) on the same claim. Local anesthetics are frequently not separately payable. Viscosupplementation (hyaluronic acid) is a joint therapy and is not applicable to bursa injection.

Common ICD-10-CM Diagnosis Codes

Code	Description	Note
M70.60	Trochanteric bursitis, unspecified hip	Use only when laterality truly unspecified.
M70.61	Trochanteric bursitis, right hip	Right GTPS; laterality documented.
M70.62	Trochanteric bursitis, left hip	Left GTPS; laterality documented.
M76.00-M76.02	Gluteal tendinitis (by laterality)	Associated gluteal tendinopathy component of GTPS.
M25.551 / M25.552	Pain in right / left hip	Differential; not a substitute when bursitis is documented.

Modifiers, POS & ASC

Element	Guidance
Modifier 50	Applies to 20610/20611 for bilateral injection (per payer instruction); or report RT and LT.
Modifier 25	For a significant, separately identifiable E/M on the same day.
Modifier RT / LT	Document the injected side when not using modifier 50.
Modifier 26 / TC	Only if reporting professional or technical component separately (uncommon in this setting).
Place of Service	POS 11 (office) is typical; POS 22 or 24 where applicable.
ASC considerations	Predominantly office-based; ASC use is uncommon for this injection.

Clinical Documentation Checklist

Point tenderness at the greater trochanter.
Provocative findings (resisted abduction / side-lying).
Laterality (RT / LT).
Conservative therapy trial and outcome.
Pre-injection numeric pain score.
Guidance modality documented.
Ultrasound: permanent image and report retained (for 20611).
Injectate name, concentration, dose.
Post-injection pain score and percent relief.
Correct code (20610 / 20611 / +77002) mapped to guidance.
Laterality-specific diagnosis (M70.6-).
Functional goal documented.

Procedure Comparison

Feature	Trochanteric Bursa Injection	Trigger Point Injection	Hip Joint Injection
Target	Major peritrochanteric bursa	Skeletal muscle	Hip joint (intra-articular)
Typical CPT®	20610 / 20611	20552 / 20553	20610 (often + guidance)
Ultrasound guidance	Bundled in 20611	Usually none	Often used
Modifier 50 (bilateral)	Applies	Does not apply	Applies
Prior auth	Usually none	Usually none	Sometimes (esp. fluoro/US)
Coverage focus	GTPS + conservative care	Myofascial findings	Hip pathology + conservative care

GoHealthcare Clinical Insights

Fix the code family first. The most common upstream error is billing a bursa injection with a trigger point code because the clinician conceptualizes it as a soft-tissue injection. Train providers and coders that the trochanteric bursa is a major bursa and belongs to the arthrocentesis family (20610/20611). Let guidance drive the code, not the other way around. Decide the guidance modality clinically, then map it: landmark to 20610, ultrasound to 20611 (with retained image), fluoroscopy to 20610 plus 77002. This single mapping eliminates the most frequent guidance denials. Set expectations around tendinopathy. Framing GTPS as gluteal tendinopathy in the record supports concurrent rehabilitation, explains partial or transient corticosteroid response, and strengthens the necessity narrative for a staged treatment plan.

GoHealthcare Leadership Perspective

Trochanteric bursa injection is a high-frequency, low-complexity service whose revenue integrity turns almost entirely on two front-end decisions: the code family and the guidance mapping. Because prior authorization rarely applies, there is no external system forcing those decisions to be correct, so the organization must supply the discipline internally. The leadership priorities are a coding rule that routes bursa injections to the arthrocentesis family, a guidance-to-code mapping embedded in the charge-capture workflow, and a documentation standard that captures conservative care and laterality. Where ultrasound guidance is used, an image-retention checkpoint protects the 20611 claim. These controls convert a deceptively simple service into a dependable, audit-ready one.

GoHealthcare Prior Authorization Insight

The authorization insight here is that the controls are almost entirely retrospective. There is little to authorize, but there is a great deal to document: conservative care, laterality, guidance justification, and frequency. Practices that treat this as a no-friction service accumulate denials for exactly those omissions. Our quality-assurance approach applies a retrospective-authorization mindset: confirm the conservative-care gate is satisfied and visible, confirm the guidance modality is mapped to the correct code with any required image retained, and confirm the diagnosis is laterality-specific - all before the claim drops. This front-loads the documentation the payer will later demand on review.

GoHealthcare Case Study

The following case is a composite created for education. It does not depict any actual patient or organization.

Clinical Scenario

A patient with chronic right lateral hip pain, worse on stairs and when lying on the affected side, underwent ultrasound-guided right trochanteric bursa injection after failing physical therapy. The practice billed 20610 with 76942 and an unspecified hip-pain diagnosis.

Documentation & Coding Challenges

The claim denied on multiple grounds: the ultrasound-guided injection should have been reported with 20611 rather than 20610 plus 76942; the diagnosis defaulted to generic hip pain rather than a laterality-specific trochanteric-bursitis code; and the retained ultrasound image was not included in the submitted record.

Payer & Prior Authorization Barriers

No prior authorization was required, so no checkpoint had validated the guidance-to-code mapping, the diagnosis specificity, or the image retention before submission.

Resolution Strategy

The practice corrected the claim to 20611 with M70.61, attached the retained ultrasound image and report, and documented the conservative-care trial. Prospectively, it built a guidance-to-code mapping into charge capture, a laterality-specific diagnosis requirement, and an ultrasound image-retention checkpoint.

Outcome & Lessons Learned

The corrected claim was paid, and guidance-related denials for joint and bursa injections declined across the practice. The lesson: for major-bursa injections, the guidance-to-code mapping and diagnosis specificity are the decisive controls, and both must be enforced without a prior-authorization prompt.

GoHealthcare Best Practices

Route trochanteric bursa injections to the arthrocentesis family (20610/20611), never trigger point codes.
Map guidance to code: landmark to 20610, ultrasound to 20611 (retain image), fluoroscopy to 20610 plus 77002.
Require laterality-specific diagnosis coding (M70.61 / M70.62) and avoid generic hip-pain codes.
Document conservative care and its outcome before the injection.
Enforce an ultrasound image-retention checkpoint for every 20611 claim.
Track cumulative same-site corticosteroid injections and justify frequency.

Common Mistakes

Billing a trigger point code for a bursa injection.
Reporting 20610 plus 76942 for an ultrasound-guided injection instead of 20611.
Billing 20611 without retaining the required permanent image and report.
Using an unspecified or generic hip-pain diagnosis instead of a laterality-specific bursitis code.
Submitting the non-billable parent M70.6 without a fifth character.
Omitting the conservative-care trial from the record.
Forgetting that modifier 50 applies for bilateral injection with this code family.
Repeating same-site corticosteroid injections without justifying frequency.

Pearls and Pitfalls

Pearls	Pitfalls
Treat the trochanteric bursa as a major bursa (20610/20611).	Reaching for a trigger point code out of habit.
Map guidance to code before charge capture.	Adding 76942 to an ultrasound-guided injection.
Retain the ultrasound image for every 20611.	Billing 20611 with no image on file.
Code laterality (M70.61 / M70.62) precisely.	Defaulting to generic hip pain (M25.55-).
Remember modifier 50 applies here for bilateral.	Assuming bilateral rules match the trigger point codes.

Frequently Asked Questions

What CPT code is used for a trochanteric bursa injection?

20610 for a landmark-guided injection and 20611 when ultrasound guidance is used with a permanent recorded image and report. The trochanteric bursa is a major bursa.

Is this a trigger point injection?

No. A trochanteric bursa injection is a major joint/bursa injection (20610/20611), not a trigger point injection (20552/20553).

How do I code ultrasound-guided injection?

Report 20611, which includes the ultrasound guidance. Do not report 20610 plus 76942 for an ultrasound-guided injection.

How do I code fluoroscopic guidance?

Report 20610 with 77002. Fluoroscopy is the exception where an add-on guidance code is reported.

Does modifier 50 apply for bilateral injection?

Yes, modifier 50 (or RT and LT) applies to 20610/20611 for bilateral injection, per payer instruction. This differs from the trigger point codes, which do not use modifier 50.

What ICD-10 code should I use?

M70.61 (right hip) or M70.62 (left hip); M70.60 only when laterality is truly unspecified. The parent M70.6 is not billable.

Can I use a generic hip-pain code?

Not when trochanteric bursitis is documented. Code the specific diagnosis (M70.6-), not a generic hip-pain code (M25.55-).

Does this procedure require prior authorization?

Usually not. Verify plan-specific corticosteroid-injection rules and any conservative-care conditions.

Is conservative care required first?

Frequently. Several policies condition coverage on documented failure of conservative measures, so the trial should be visible in the record before the injection.

What conservative care is expected?

Activity modification, physical therapy with abductor strengthening, NSAIDs, and weight management where relevant; document the trial and outcome.

Is ultrasound guidance always necessary?

No. The bursa is often palpable, and landmark injection is common. Document a rationale when ultrasound guidance is used, and retain the image required for 20611.

How is the corticosteroid billed?

With the appropriate J-code (for example J1030, J1040, or J3301) on the same claim as the injection.

Does viscosupplementation apply here?

No. Hyaluronic acid is a joint therapy (for example knee osteoarthritis) and is not used for bursa injection.

How often can this injection be repeated?

Repeated same-site corticosteroid injections are limited by payer policy; document the clinical justification and response when repeating.

Should I document laterality even if I use modifier 50?

Yes. Laterality-specific diagnosis coding and clear documentation of the injected side(s) support the claim regardless of modifier.

What imaging supports the diagnosis?

Ultrasound or MRI may show bursal fluid, bursal wall thickening, or gluteal tendinopathy; document findings when obtained, though imaging is not required in every clear case.

Can I bill an E/M on the same day?

Only for a significant, separately identifiable evaluation beyond the injection work, with modifier 25.

What is greater trochanteric pain syndrome?

A clinical syndrome of lateral hip pain that encompasses trochanteric bursitis and gluteal tendinopathy; it is coded to the M70.6- family.

Why did my 20611 claim deny?

Common causes are a missing retained ultrasound image, an unsupported guidance rationale, or an unspecified diagnosis. Retain the image and code specifically.

What single control most reduces denials here?

A guidance-to-code mapping embedded in charge capture, paired with laterality-specific diagnosis coding.

Should suspected tendon tear change management?

Yes. Suspected gluteal tendon tear may make corticosteroid injection inadvisable; document the assessment and consider imaging.

Is a diagnostic block needed before injection?

No separate diagnostic block is required; the therapeutic injection commonly includes a local-anesthetic component that also aids diagnosis.

Key Takeaways

Code as a major joint/bursa injection: 20610 (landmark) or 20611 (ultrasound, guidance bundled) - never a trigger point code.
Ultrasound guidance is included in 20611; do not add 76942. Fluoroscopy is 20610 plus 77002.
Modifier 50 for bilateral injection applies to this code family.
Use laterality-specific diagnosis codes (M70.61 / M70.62); the parent M70.6 is not billable.
Document conservative care before injection; it is frequently the coverage gate.
Retain the permanent ultrasound image for every 20611 claim.
Frame GTPS as including gluteal tendinopathy to support staged, rehabilitation-based care.

Future Outlook

The clinical reframing of GTPS from isolated bursitis toward gluteal tendinopathy is likely to continue shaping both practice and payer expectations, with growing emphasis on exercise-based rehabilitation and more selective use of corticosteroid injection. Ultrasound will remain the dominant guidance modality where guidance is used, reinforcing the importance of

image retention for 20611. As payers refine frequency and conservative-care requirements for site-specific corticosteroid injections, practices with disciplined documentation and guidance-to-code mapping will absorb these changes without revenue disruption.

References

American Medical Association. CPT® 2026 Professional Edition (20610, 20611, 77002). https://www.ama-assn.org/practice-management/cpt AAPC. Coding guidance - trochanteric bursa injection reported with 20610. https://www.aapc.com/codes/coding-newsletters/my-orthopedic-coding-alert/reader-question-equate-20610-for-trochanteric-bursa-injection-article ICD-10-CM 2026, M70.60 - M70.62 (Trochanteric bursitis). https://www.icd10data.com/ICD10CM/Codes/M00-M99/M70-M79/M70-Centers for Medicare & Medicaid Services. Medicare Coverage Database (joint/bursa injection LCDs and articles by MAC). https://www.cms.gov/medicare-coverage-database Cigna. Medical Coverage Policy 0063 - Local Injection Therapy. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_0063_coveragepositioncriteria_local_injection_therapy.pdf Outsource Strategies. Coding Musculoskeletal Ultrasound-Guided Procedures. https://www.outsourcestrategies.com/resources/coding-musculoskeletal-ultrasound-guided-procedures/American Academy of Orthopaedic Surgeons (AAOS). https://www.aaos.org American Society of Interventional Pain Physicians (ASIPP). https://www.asipp.org

Reading Recommendations

AMA CPT® guidance distinguishing 20610, 20611, and add-on guidance codes.
Your MAC's joint/bursa corticosteroid-injection LCD and article, including conservative-care and frequency requirements.
Commercial local-injection-therapy and ultrasound-guidance medical policies for your top payers.
AAOS and specialty-society guidance on greater trochanteric pain syndrome and gluteal tendinopathy.

Recommended Downloads

Trochanteric Bursa Injection Structured Procedure Note Template.
Guidance-to-Code Mapping Quick-Reference (20610 / 20611 / +77002).
Conservative-Care Documentation Checklist (GTPS).
Ultrasound Image-Retention Compliance Checklist.

Visual Recommendations

High-level illustration of the greater trochanter, trochanteric bursa, and gluteal tendon insertions.
Guidance-to-code decision tree (landmark / ultrasound / fluoroscopy).
GTPS work-up and treatment-staging flowchart.
Coding matrix: 20610 / 20611 / 77002 with modifiers and laterality.
Conservative-care and frequency coverage matrix by payer.
Documentation checklist infographic for point-of-care use.

Educational Disclaimer

This document is intended for educational and operational reference purposes only. It does not replace physician clinical judgment, payer policy review, legal advice, or official CMS guidance, and it is not a procedural or physician training manual. Coverage policies, coding guidance, frequency limitations, and reimbursement requirements change frequently and vary by payer, plan, and jurisdiction; all codes and coverage criteria must be independently verified against the applicable payer policy and current regulatory sources before submission. CPT® is a registered trademark of the American Medical Association. GoHealthcare Practice Solutions assumes no liability for actions taken in reliance on this educational material.

This webpage does not replace physician judgment, official payer policy, legal advice, or current coding guidance. CPT® is a registered trademark of the American Medical Association.